Sinopharm unit cleared to study first mRNA COVID shot in China

Coronavirus or sars-cov-2 virus cell with messenger RNA or mRNA and syringe on blue background 3D rendering illustration with copy space. Vaccination or vaccine, immunity, pandemic, science, medicine, medical technology concept.

libre de droit

  • China National Biotec Group (CNBG) a subsidiary of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY), announced Friday that authorities in China greenlighted clinical trials for the country's first mRNA-based COVID-19 vaccine targeting the Omicron variant.
  • China's National Medical Products

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.